Colony Capital Inc. (CLNY) Vs. Novavax Inc. (NVAX): Those Ticking Clocks

Colony Capital Inc. (NYSE: CLNY) shares are -40.21% down in the year-to-date (YTD) period and have moved 1.76% or $0.05 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +117.29% lower. Comparatively, the stock is -44.10% down YTD and 58.66% over the trailing 3-month period. If we look at the shorter duration, its week performance is 5.58% and 53.51% over the month.


5 Stocks to make up the PERFECT 2021 gold portfolio

Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.

Click here to download your free report right away

Sponsored


Analyst Recommendations

2 analysts offering the recommendations for the stock have a consensus rating of 2.50 to suggest that the CLNY stock is a “Moderate Buy. 0 of the 2 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.

The stock currently trades at $2.89 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $3.25. The forecasts give the Colony Capital Inc. stock a price target range of $4.00 on the higher side while at least one analyst think the stock could plunge to a low of $2.50. The two limits represent an upside potential of 27.75% or -15.6%.

Earnings Forecast

Analysts estimate the earnings to decrease -1,102.80% in the current quarter to -$0.21, up from the -$1.16 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$5.38, down -30.50% from -$2.41 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.19 and -$0.19. Wall Street estimates earnings per share to be at an average of -$0.64 for the next year.

Insider Transactions Summary

According to SEC data, total insider shares purchases at the company stands at 16 over the last 12 months, while SEC filings reveal that there have been 10 insider sales over the same period. Insiders have purchases 5,070,127 shares while those sold by company executives and officers stand at 1,387,968. The last 3 months have seen insiders trade a total of 220,000 and 0 in purchases and sales respectively.

Ganzi Marc C, a CEO & President at the company, bought 100,000 shares worth $0.27 million at $2.70 per share on Aug 14. The Chief Operating Officer had earlier bought another 25,000 CLNY shares valued at $69980.0 on Aug 17. The shares were bought at $2.80 per share. Sanders Ronald M. (Exec. VP – CLO & Secretary) bought 75,000 shares at $2.57 per share on Aug 12 for a total of $0.19 million while Wu Jacky, (CFO & Treasurer) bought 20,000 shares on Aug 11 for $49600.0 with each share fetching $2.48.

Novavax Inc. (NASDAQ:NVAX), on the other hand, is trading around $119.26 with a market cap of $8.77B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $227.60 and spell out a more modest performance – a 47.6% return. Some analysts are even forecasting $9.08 per share in earnings this year on a short term (1 year) basis.

Let us briefly look at the Novavax Inc. (NVAX) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.

Company balance sheet and cash flow

NVAX’s operating expenses over the recent quarter were at -$17.03 million. This represented a 147.91% of the company’s total revenues which amounted $35.54 million. With this in place, we can see that the company’s diluted EPS declined -$0.30 on the year-over-year period, shrinking to -$1.69 as given in the last earnings report.

In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $932.23 million from $328.07 million over the previous quarter. Short term investments amounted to $77.9 million while total current assets were at $636.38 million. The cash flow from operating activities totaled $92.52 million, significantly higher than the -$80.62 million reported in the year-ago quarter. The company’s free cash flow for the quarter was $88.64 million.

Insider activity

Insiders have transacted a total of 61 times at Novavax Inc. over the last 6 months, with insider purchases undertaken 34 times and accounting for 202,410 shares. Insider sales totaled 197,330 shares over the same period, with these deals completed in 27 transactions. Looking at these numbers, we realize that net purchases over that period are 7.0 shares. Insiders now hold a total of 222.25k shares after the latest sales, with 5.10% net shares purchased.

Major holders

Insiders own 0.20% of the company shares, while shares held by institutions stand at 53.00% with a share float percentage of 55.24M. Investors are also buoyed by the number of investors in a company, with Novavax Inc. having a total of 130 institutions that hold shares in the company.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free